Fertility preservation in patients undergoing gonadotoxic treatments: a Canadian Fertility and Andrology Society clinical practice guideline

Reprod Biomed Online. 2024 May;48(5):103767. doi: 10.1016/j.rbmo.2023.103767. Epub 2023 Dec 15.

Abstract

The management of young patients with cancer presents several unique challenges. In general, these patients are ill prepared for the diagnosis and the impact on their fertility. With the improved survival for all tumour types and stages, the need for adequate fertility counselling and a multidisciplinary approach in the reproductive care of these patients is paramount. Recent advances in cryopreservation techniques allow for the banking of spermatozoa, oocytes, embryos and ovarian tissue without compromising survival. This Canadian Fertility and Andrology Society (CFAS) guideline outlines the current understanding of social and medical issues associated with oncofertility, and the medical and surgical technologies available to optimize future fertility.

Keywords: Chemotherapy; Embryo cryopreservation; Gamete cryopreservation; Gonadotrophin-releasing hormone agonist; Ovarian tissue cryopreservation; Radiation.

Publication types

  • Practice Guideline

MeSH terms

  • Andrology / standards
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / adverse effects
  • Canada
  • Cryopreservation* / methods
  • Cryopreservation* / standards
  • Female
  • Fertility Preservation* / methods
  • Fertility Preservation* / standards
  • Humans
  • Male
  • Neoplasms* / drug therapy

Substances

  • Antineoplastic Agents